Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,992,860 papers from all fields of science
Search
Sign In
Create Free Account
Response Evaluation Criteria in Solid Tumors Version 1.0
Known as:
RECIST 1.0
A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000, which is an objective response…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Clinical Data Interchange Standards Consortium Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract P4-22-14: Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer
A. Clark
,
Xingmei Wang
,
+13 authors
A. Demichele
2017
Corpus ID: 78566162
Background: The Cyclin D/CDK4/6/Rb axis is dysregulated in breast cancer (BC). Palbociclib (P) is an oral agent that specifically…
Expand
2016
2016
Abstract P6-13-08: Palbociclib and paclitaxel on an alternating schedule for advanced breast cancer: Results of a phase Ib trial
A. Clark
,
P. O'Dwyer
,
+12 authors
A. Demichele
2016
Corpus ID: 76759886
Background: Palbociclib (P) is an oral CDK 4/6 inhibitor (CDKi) that was recently FDA approved in combination with endocrine…
Expand
2013
2013
Evaluierung der Inter-/Intrareader Reproduzierbarkeit unterschiedlich erfahrener Untersucher beim Therapiemonitoring von Pleuramesotheliomen mittels mRECIST, RECIST 1.0, RECIST 1.1 und WHO Kriterien
L. Stahlhut
,
A. Bunck
,
+7 authors
T. Persigehl
2013
Corpus ID: 76266050
2013
2013
Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer
H. Burris
,
M. Gnant
,
+8 authors
H. Rugo
2013
Corpus ID: 71905475
Introduction: The BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, EVE, with…
Expand
2012
2012
Comparison of RECIST 1.1, RECIST 1.0 and WHO Criteria for Peripheral Lung Cancer Response to Treatment
Zhang Yan
2012
Corpus ID: 76485618
Purpose To evaluate the consistency of WHO, RECIST 1.0 and RECIST 1.1 criteria in evaluating peripheral lung cancer, and to…
Expand
2012
2012
Impact of early treatment response assessment on prediction of overall survival in metastatic prostate cancer: RECIST 1.0 vs. PERCIST 1.0
H. Jadvar
,
Bhushan Desai
,
+5 authors
S. Groshen
2012
Corpus ID: 74571659
2012
2012
Comparative study of induction chemotherapy and chemoradiotherapy in the treatment of limited-disease small cell lung cancer with ipsilateral pleural effusion
Ying Liu
,
Xuerong Zuo
,
Caixia Zhang
,
Ying Cheng
2012
Corpus ID: 58157928
ObjectiveThe aim of the study was to explore the effects and side effects of induction chemotherapy followed by chemoradiotherapy…
Expand
2011
2011
PD07-07: Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a…
S. Lam
,
S. D. de Groot
,
+13 authors
E. Boven
2011
Corpus ID: 73227103
Background: First-line treatment of HER2−negative LR/MBC with paclitaxel (T) and bevacizumab (A) has demonstrated improved…
Expand
2011
2011
Abstract P5-20-08: Phase II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC)
L. Schwartzberg
,
K. Tauer
,
+6 authors
M. Walker
2011
Corpus ID: 72491570
Background: Ixa is a novel microtubule blocking epothilone with activity in taxane and anthracycline-resistant MBC. D is a potent…
Expand
Review
2010
Review
2010
Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E).
L. Mileshkin
,
B. Hughes
,
+7 authors
Bernard M. Fine
2010
Corpus ID: 79266779
7567 Background: Assessing the efficacy of molecularly targeted agents, especially in the absence of tumor shrinkage, remains a…
Expand